Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma-Reference-Cited by-同舟云学术

Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

Published:2015-01-09 Issue:3 Volume:262 Page:742-751
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Duerinck Johnny,Clement Paul M.,Bouttens Frank,Andre Chantal,Neyns Bart,Staelens Yves,Van Fraeyenhove Frank,Baurain Jean-Francois,Luce Sylvie,D’hondt Lionel,Joosens Eric,Specenier Pol,Verschaeve Vincent,Filleul Bertrand,Vroman Philippe,Stragier Barbara,Rogiers Anne

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-014-7633-z.pdf

Reference40 articles.

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

3. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578

4. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6(3):227–235

5. Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29–38

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis;Experimental and Therapeutic Medicine;2023-08-03

2. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial;Journal for ImmunoTherapy of Cancer;2021-06

3. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma;Molecular Oncology;2020-03-18

4. Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study;Neuro-Oncology;2019-12-17

5. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study;Journal of Neuro-Oncology;2019-07-19